



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

MICROCYN™ RECEIVES APPROVAL AS A STERILANT FROM MEXICAN MINISTRY OF HEALTH

“Disruptive” disinfectant/antiseptic technology from Oculus Innovative Sciences approved for expanded use in sterilization of wounds and hard surfaces.

PETALUMA, CA-- (Jan. 9, 2004)— Hoji Alimi, president and founder of Oculus Innovative Sciences (www.oculusis.com), today announced that the Mexican Ministry of Health has approved the company’s Microcyn™ technology for commercial use as a sterilant.

Microcyn, having already been approved for sale and distribution by the Mexican Ministry of Health as a disinfectant in July 2003, safely eradicates viruses, bacteria, spores and molds quickly and effectively. Based on this initial approval, Microcyn has been used in Mexico as a commercial disinfectant for hard surfaces and medical devices, as well as an antiseptic for use on patients for the irrigation of wounds and in pre-operative skin preparation. Due to its non-toxic nature, disposal of Microcyn doesn’t require costly environmental processes usually associated with more toxic competitive products. In addition, Microcyn holds great promise in the areas of food sterilization and anti-bioterrorism.

“We are excited and appreciate the Mexican Ministry of Health’s prompt approval of Microcyn for the sterilant market,” said Alimi. “The fast approval process speaks volumes about the market for a non-toxic disinfectant/antiseptic that effectively kills microorganisms. Mexico’s approval opens up additional markets for us, especially for patient health care in Mexico, a huge opportunity in light of Mexico’s current population of approximately 100 million people.”

The additional approval as a sterilant opens broader markets for Microcyn for the sterilization of wounds and hard surfaces.

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative technologies that globally re-define the disinfectant and antiseptic markets. Oculus has developed the

revolutionary Microcyn disinfectant and antiseptic with broad applications in such diverse markets as consumer, medical, dental, veterinarian, cosmetic, wound healing, food processing and anti-bio-terrorism. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V. Please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.